TmPSMA-02 in mCRPC

This study tests TmPSMA-02, a targeted radiation therapy that delivers radioactive material directly to prostate cancer cells using a molecule that seeks out a protein called PSMA. It is being studied in men with metastatic prostate cancer that no longer responds to hormone therapy (called mCRPC). **You may be eligible if...** - You are a man with metastatic prostate cancer that has stopped responding to hormone treatments - Your cancer tests positive for the PSMA protein on imaging - You have received prior standard treatments - Your kidneys and other organs are functioning well enough **You may NOT be eligible if...** - Your cancer does not show adequate PSMA expression - You have had too much prior radiation to certain organs - You have significant kidney disease - You are on certain other cancer treatments that cannot be paused Talk to your doctor to see if this trial is right for you.